Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo
Alcohol and Alcoholism · 2024
DOI: 10.1093/alcalc/agae044 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alcohol and Alcoholism, 2024. Verfasst von Annabel Kady und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 51563, Los Angeles, CA 90095-1563, United States. Hauptthemen laut MEDLINE: Naltrexone, Reward, Varenicline, Alcoholism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.
Abstract (Originalsprache)
Introduction
This study aims to clarify differences in mood, craving, and treatment response between reward and relief/habit individuals in a study of naltrexone, varenicline, and placebo. We hypothesized that relief/habit individuals would have a poorer mood during early abstinence and higher levels of alcohol craving than reward individuals. We hypothesized that reward individuals would demonstrate better drinking outcomes on naltrexone versus placebo.
Methods
Data were culled from a randomized, double-blind, placebo-controlled human trial of 53 individuals (18F/16M) with alcohol use disorder randomized to varenicline (n = 19), naltrexone (n = 15), or matched placebo (n = 19). In this 6-day practice quit trial, participants attempted to abstain from drinking and completed daily diaries. Participants were classified into reward or relief/habit subgroups based on self-reported motivation for drinking. Multilinear models tested differences in mood and alcohol craving between reward and relief/habit individuals. General linear models tested differences between reward and relief/habit individuals’ drinking outcomes on each medication versus placebo.
Results
Relief/habit individuals showed decreases in positive mood and increases in negative mood over the quit attempt across medications, compared to reward individuals (P’s < .05). Reward individuals’ tension decreased on naltrexone, while relief/habit individuals’ tension remained stable (F = 3.64, P = .03). Reward individuals in the placebo group had higher percent days abstinent than relief individuals in the placebo group (P < .001).
Discussion
This study suggests relief/habit individuals’ mood worsens during early abstinence. Our finding that reward individuals’ tension decreased on naltrexone and increased on placebo may suggest a clinical response to the medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 51563, Los Angeles, CA 90095-1563, United States.
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 757 Westwood Plaza #4, Los Angeles, CA 90095, United States.
- Brain Research Institute, University of California, Los Angeles, 695 Charles E Young Dr. S, Los Angeles, CA 90095, United States.
ORCID-Profile: Annabel Kady, Erica N Grodin, Lara A Ray
Förderung
- NIDA NIH HHS
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Kady, A., Grodin, E. N., & Ray, L. A. (2024). Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agae044
Vancouver
Kady A, Grodin EN, Ray LA. Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo. Alcohol and Alcoholism. 2024. doi:10.1093/alcalc/agae044
BibTeX
@article{Kady2024,
author = {Kady, Annabel and Grodin, Erica N and Ray, Lara A},
title = {Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo},
journal = {Alcohol and Alcoholism},
year = {2024},
doi = {10.1093/alcalc/agae044}
}
EUVIMED